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Background: The carboxy-terminal 42 kDa region of Plasmodium vivax merozoite surface protein-1 (PvMSP-142) is a
leading candidate antigen for blood stage vaccine development. However, this region has been observed to be
highly polymorphic among filed isolates of P. vivax. Therefore it is important to analyse the existing diversity of this
antigen in the field isolates of P. vivax. In this study, the genetic diversity and natural selection in PvMSP-142 among
P. vivax Korean isolates were analysed.
Methods: A total of 149 P. vivax-infected blood samples collected from patients in Korea were used. The region
flanking PvMSP-142 was amplified by PCR, cloned into Escherichia coli, and then sequenced. The polymorphic
characteristic and natural selection of PvMSP-142 were analysed using the DNASTAR, MEGA4 and DnaSP programs.
Results: A total of 11 distinct haplotypes of PvMSP-142 with 40 amino acid changes, as compared to the reference
Sal I sequence, were identified in the Korean P. vivax isolates. Most of the mutations were concentrated in the
33 kDa fragment (PvMSP-133), but a novel mutation was found in the 19 kDa fragment (PvMSP-119). PvMSP-142 of
Korean isolates appeared to be under balancing selection. Recombination may also play a role in the resulting
genetic diversity of PvMSP-142.
Conclusions: PvMSP-142 of Korean P. vivax isolates displayed allelic polymorphisms caused by mutation,
recombination and balancing selection. These results will be useful for understanding the nature of the P. vivax
population in Korea and for development of a PvMSP-142 based vaccine against P. vivax.
Keywords: Plasmodium vivax, Merozoite surface protein-1 C-terminal 42 kDa fragment, Genetic diversity, Natural
selection, KoreaBackground
Merozoite surface protein-1 (MSP-1) is a high molecular
mass protein abundantly expressed on the surface of the
merozoite of malaria parasites and it plays a critical role
in the erythrocyte invasion of the parasites [1]. It is
synthesized as a large precursor during schizogony and is
subsequently processed via proteolytic cleavage into four
major polypeptides of approximately 83, 30, 38, and* Correspondence: tongsookim@inha.ac.kr; bkna@gnu.ac.kr
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reproduction in any medium, provided the or42 kDa from the N-terminus to C-terminus [1,2]. During
the invasion process, the C-terminal 42 kDa fragment
(MSP-142) is further processed into 33 kDa (MSP-133)
and 19 kDa (MSP-119) fragments, and the latter remains
on the merozoite surface and is carried into the invaded
erythrocytes, but all the other fragments are released
from the merozoite surface [3,4]. Individuals naturally
infected with Plasmodium vivax acquire humoral im-
mune responses against the C-terminal part of MSP-1,
MSP-119 or MSP-142 [5-10]. Antibodies that recognize
the C-terminal region of Plasmodium falciparum MSP-1
inhibit invasion of the merozoites into host erythrocytes
in vitro [11-14], and immunization of experimental ani-
mals with MSP-119 confers protective immunity [15,16].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing candidate antigen for blood stage vaccine develop-
ment [1,17-19]. However, genetic polymorphisms
encoding this region, within and among the P. vivax
population, are one of the important factors impeding
vaccine development.
Vivax malaria had been endemic on the Korean Penin-
sula for centuries [20], but was eradicated in South
Korea by 1979 as a result of intensive efforts led by the
World Health Organization and Korean National Mal-
aria Eradication Programme. However, vivax malaria re-
emerged in South Korea in 1993 and the outbreak has
continued with fluctuating numbers of annual indigen-
ous cases with the total number of cases up to 23,000
[21]. During the early period of the re-emergence, most
malaria cases were restricted to military personnel and
veterans who served near the Demilitarized Zone
(DMZ), and the geographic distribution was limited to
the DMZ and adjacent areas where no civilians reside
[22]. In spite of the significant decrease in the number of
malaria cases among military personnel since the re-
emergence, mainly resulting from aggressive chemo-
prophylaxis, the number of malaria cases in the civilian
population has increased and the geographic distribution
is expanding into southward cities and counties nearby
the DMZ, a pattern indicating the establishment of local
transmission in South Korea [21,23].
Although genetic polymorphisms in the central repeat
region of MSP-1 in Korean P. vivax isolates has been
previously analysed [24-26], little information is available
regarding the genetic polymorphism of MSP-142 among
Korean P. vivax population. In this study, the genetic
polymorphisms and natural selection in MSP-142 among
P. vivax Korean isolates were analysed to gain in-depth
understanding of the nature of Korean P. vivax popula-
tion. The results suggested that a significant level of
genetic diversity exists in the MSP-142, particularly in
MSP-133, among Korean P. vivax isolates and the region
is undergoing a natural selection process.
Methods
Blood samples
A total of 149 blood samples were collected from Korean
patients infected with P. vivax in Korea between 1999
and 2010. Plasmodium vivax infection was identified by
microscopic examination of thin and thick blood smears
and confirmed by polymerase chain reaction (PCR) [27].
All the patients have a febrile illness and have not been
abroad at least in recent two years when their blood
samples were collected. About 5 ml of blood was col-
lected from each individual. The blood was separated
into packed cells and plasma and then stored at −80°C
until use. Blood collections performed for this study were
conducted following informed consent of the patients andadhering to the institutional ethical guidelines reviewed
and approved by either the Ethics committee of Gachon
University of Medicine and Science or Inha University
School of Medicine.
Genomic DNA extraction and amplification of PvMSP-142
Genomic DNA was extracted from 200 μl of blood sam-
ple using a QIAamp Blood Kit (Qiagen, Valencia, CA,
USA). Amplification of PvMSP-142 was performed using
two rounds of PCR with primers described previously
[28]. The first round PCR primers were 5'-ACGTAGCA
GCAAAAGCGCAG-3' and 5'-GCAACATGAGCAAC
AAGAAGG-3' and the primers for nested PCR were 5'-
ACTACGCCGAGGACTACGAC-3' and 5'-AGGACAAG
CTTAGGAAGCTGG-3'. The amplification reaction for
each round of PCR was performed using the following
thermal cycling conditions: 94°C for 5 min, 30 cycles at
94°C for 1 min, 50°C for 1 min, and 72°C for 1.5 min, and
followed by a final extension at 72°C for 10 min. Ex Taq
DNA polymerase (Takara, Otsu, Japan) was used in all
PCR reactions in order to eliminate any possible nucleo-
tide misincorporation. The PCR product was analysed
on a 1.2% agarose gel, purified from the gel, and then
ligated into the T&A cloning vector (Real Biotech Co-
operation, Banqiaa City, Taiwan). Each ligation mixture
was transformed into Escherichia coli DH5α competent
cells and positive clones with the appropriate insert were
selected. The nucleotide sequences of the cloned insert
were analysed by automatic DNA sequencing. In order
to verify the sequences, at least two clones from each
isolate were sequenced in both directions. Some
isolates underwent three-fold sequence coverage to
confirm the existence of rare polymorphisms. The nucleo-
tide sequences reported in this study have been deposited
in the GenBank database under the accession numbers
JQ446312-JQ446322.
Sequence and phylogenetic analysis
Nucleotide and deduced amino acid sequences of PvMSP-
142 were analysed using EditSeq and SeqMan in the
DNASTAR package (DNASTAR, Madison, WI, USA). The
phylogeny tree was constructed using the neighbour-
joining method in MEGA4 [29]. Bootstrap proportions
were used to assess the robustness of the tree with 1,000
bootstrap replications.
DNA sequence polymorphism analysis
DNA sequence polymorphism analysis was performed
on the 149 PvMSP-142 sequences. The number of segre-
gating sites (S), haplotypes (H), haplotype diversity (Hd),
nucleotide diversity (π), and the average number of pair-
wise nucleotide differences within the population (K)
were estimated using DnaSP ver. 5.10.00 [30]. The π was
calculated on a sliding window of 100 bases with a step
size of 25 bp to estimate the stepwise diversity across
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synonymous (dN) substitutions were estimated and com-
pared by the Z-test (P< 0.05) in MEGA4 program [29]
using the Nei and Gojobori’s method [31] with the Jukes
and Cantor correction. Tajima’s D test [32] was per-
formed with DnaSP ver. 5.10.00 to evaluate the neutral
theory of evolution. Fu and Li’s D and F statistics [33]
were also analysed using DnaSP ver. 5.10.00 [30].
Recombination parameters and linkage disequilibrium
The recombination parameter (R), which included the ef-
fective population size and probability of recombination
between adjacent nucleotides per generation, and the
minimum number of recombination events (Rm) were
measured using DnaSP ver. 5.10.00 [30]. Linkage dis-
equilibrium (LD) between different polymorphic sites
was computed in terms of the R2 index.
Results
Genetic polymorphisms and amino acid changes
The region corresponding to PvMSP-142 was amplified
from the 149 P. vivax Korean isolates. Nucleotide se-
quence analysis of the 149 PvMSP-142 sequences
revealed that there was no size variation between the
sequences but they showed polymorphic characteristics.
A sequence analysis of the 149 PvMSP-142 sequences
resulted in their classification into 11 different haplo-
types (haplotypes 1–11) with amino acid changes at 40
positions as compared to the reference Sal I sequence
(Figure 1). Of the 40 amino acid changes, three were tet-
ramorphic (N1517S/A/V, D1520T/A/N and I1527M/T/
N), nine were trimorphic (T1494E/A, K1505A/T,









































































































































































































































































































Figure 1 Sequence polymorphism of PvMSP-142 in Korean Plasmodium
haplotypes of PvMSP-142 were identified in 149 P. vivax Korean isolates. Pol
(AF435593), are listed for each haplotype. The dimorphic, trimorphic and te
respectively. The total numbers of sequences for each haplotype are listedA, E1525Q/K and F1526S/L), and the others were di-
morphic (Figure 1). Most of the amino acid substitutions
were found in the PvMSP-133 region and only one di-
morphic substitution (N1692K) was identified in
PvMSP-119. Interestingly, seven amino acid changes
(N1343Y, N1427Y, L1447W, K1486R, E1603V, L1613V,
and N1692K) were unique and had not been identified
previously, and represented novel haplotypes. Sequence
analysis of the 11 haplotypes of PvMSP-142 based on the
hypervariable region also revealed that haplotypes 1–5
were essentially similar to the Belem type. However, the
others (haplotypes 6–11) were recombinant forms be-
tween Sal I and Belem, which had at least one possible
recombination site in their sequences. Phylogenetic ana-
lysis revealed that the Korean PvMSP-142 haplotypes
were clustered into five clades, a Belem-type and four
scattered clades (Figure 2). Upon analysis of the distribu-
tion of each MSP-142 haplotype in each year, an interest-
ing finding was observed. In the isolates collected in
1999–2000, only the Belem type haplotypes of PvMSP-142
were identified. However, a recombinant type haplotype
(haplotype 7) was first identified among the isolates col-
lected in 2001, and both Belem and recombinant haplotypes
were identified thereafter with a prevalence of recombinant
haplotypes (Figure 3).Nucleotide diversity and natural selection of PvMSP-142
DNA sequence analyses were performed to determine
the nucleotide diversity and genetic differentiation at
PvMSP-142 among the Korean P. vivax isolates. The
average number of pair-wise nucleotide differences (K)
for the 1,234 bp PvMSP-142 region was 19.570 (Table 1).










































































































































































































































































































































vivax isolates. Sequence analysis revealed that a total of 11 distinct
ymorphic amino acids compared to the reference sequence, Sal I
tramorphic amino acid changes are marked in yellow, blue and red,
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Figure 2 (See legend on next page.)
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Figure 2 Phylogenetic analysis. The phylogenetic tree for the 11 haplotypes of PvMSP-142 was constructed using a neighbour-joining method
with the MEGA4 program. Numbers on the branches indicate bootstrap proportions (1,000 replicates). The new haplotypes are marked with
asterisks.
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0.01586 ± 0.00047, respectively (Table 1). Analysis of the
genetic diversity of the PvMSP-133 and PvMSP-119 frag-
ments revealed that the PvMSP-119 fragment is more
highly conserved than the PvMSP-133 fragment, indicat-
ing that most of the nucleotide diversity was concen-
trated in PvMSP-133. The overall haplotype diversity
(Hd) and nucleotide diversity (π) for PvMSP-133 was
0.873 ± 0.009 and 0.02051 ± 0.00063, respectively. To
examine whether or not natural selection contributed to
the diversity observed in PvMSP-142 within the Korean
P. vivax population, the average difference of dN-dS for
all PvMSP-142 sequences was analysed. The estimated
dN-dS was 0.0067, indicating that positive natural selec-
tion may be occurring in the PvMSP-142 of Korean iso-
lates (Table 1). PvMSP-133 and PvMSP-119 also showed
positive dN-dS values of 0.0085 and 0.0016, respectively.
In order to more closely explore natural selection in the
PvMSP-142, Tajima’s D test was applied and the value
was estimated to be 3.0268 (P< 0.01), indicating that
PvMSP-142 is under positive selection pressure (Table 1).
The Tajima’s D values for PvMSP-133 and PvMSP-119
also showed positive values of 3.0556 (P< 0.01) and
0.5504 (P> 0.1), respectively. The Fu and Li’s D and F
values for PvMSP-142 were 2.0839 (P< 0.02) and 2.9904
(P< 0.02), respectively. Analysis of the sliding window
plot (window length 100 bp, step size 25 bp) using the
DnaSP package revealed that π ranged from 0 to 0.1301
and supported our observations that most of the variations
were concentrated between nucleotide positions 400–675,
















Figure 3 Annual distribution of PvMSP-142 haplotypes during the stud
analysed by year of collection. Only Belem type haplotypes of PvMSP-142 w
identified in 2001, and both Belem-type and recombinant type haplotypesRecombination
For PvMSP-142, the minimum number of recombination
events between adjacent polymorphic sites (Rm) was five,
whereas the R between adjacent sites (Ra) and per gene
(Rb) was 0.0065 and 8.0, respectively. Similar results
were obtained when PvMSP-133 was analysed (Rm: 5, Ra:
0.0080, and Rb: 7.5). These high recombination param-
eter values suggested that meiotic recombination may be
occurring between sites, resulting in genetic diversity of
the PvMSP-142. The LD index, R
2, also declined across
the analysed region, suggesting that intragenic recombin-
ation may also be a possible factor contributing to the di-
versity observed in PvMSP-142 (Figure 4B).Discussion
A blood stage malaria vaccine ideally aims to prevent or
considerably reduce blood stage parasitaemia either by
inhibiting merozoite invasion into erythrocytes or by tar-
geted destruction of parasitized erythrocytes [19,34]. Fol-
lowing this approach, several merozoite surface proteins
(MSPs) have been considered promising candidate anti-
gens for malaria vaccine development due to their acces-
sibility by antibodies and their essential roles in
erythrocyte invasion [19]. However, the genetic diversity
of the MSPs identified within and among global isolates
has resulted in a major obstacle hampering the develop-
ment of an effective malaria vaccine. Of the MSPs, MSP-
142 is the most outstanding vaccine candidate antigen,
which is currently at an advanced stage of clinical evalu-
ation [34-37]. But, its polymorphic nature suggests that
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Figure 4 Natural selection and recombination event of PvMSP-142. (A) Sliding window plot of nucleotide diversity per site (π) comparing
the level of genetic diversity at PvMSP-142. The π values were calculated using DnaSP with a window length of 100 bp and step size of 25 bp.
(B) The linkage disequilibrium (LD) plot showing non-random association between nucleotide variants in the 149 Korean P. vivax isolates at
different polymorphic sites. The R2 values were plotted against nucleotide distance using a two-tailed Fisher’s exact test for significance.
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would be required.
In this study, the genetic diversity and natural selection
on PvMSP-142 in the 149 P. vivax Korean isolates were
analysed. The 149 sequences were classified into 11 dis-
tinct haplotypes with amino acid changes at 40 positions
as compared to the Sal I sequence. Most of the amino
acid substitutions were concentrated in the PvMSP-133
fragment and only a dimorphic change (N1692K) was
found in PvMSP-119. It is known that PvMSP-119 is
highly conserved, as observed in field isolates obtained
from different geographic regions, and only one amino
acid change (K1709E) has been reported thus far [38-41].
The amino acid change was not observed in any of the
Korean isolates, but the emergence of a new amino acid
change in PvMSP-119 in Korean isolates suggest that
PvMSP-119 could contribute to the diversity of PvMSP-142.
Of the 39 amino acid changes found in PvMSP-133 of
Korean isolates, six (N1343Y, N1427Y, L1447W,
K1486R, E1603V, and L1613V) were unique and had not
been reported previously. These unique changes
resulted in the generation of six novel haplotypes that
had not been reported so far. The sequence and phylo-
genetic analyses revealed that none of the Korean haplo-
types were identical to either the Sal I or Belem
sequences, but haplotypes 1–5 were essentially Belem
types, and the others were recombinant types between
Belem and Sal I, in which at least one recombination
may occur at the hypervariable region of PvMSP-133. Re-
cently, PvMSP-142 was differentiated into 12 distinctive
groups (group 1–12) based on sequence differences
observed in hypervariable region, but there was no evi-
dence of geographic clustering of global isolates [42].
Phylogenetic analysis of Korean PvMSP-142 haplotypessuggested they were clustered into five distinct clades with
the majority belonging to the Belem type, but no clear geo-
graphic relationship was also identified. Interestingly, the
isolates collected in 1999–2000 showed only limited haplo-
types which were closely related to the Belem type. How-
ever, a recombinant haloptype was first observed among
isolates collected in 2001. Both Belem and recombinant
types of the PvMSP-142 haplotypes were identified there-
after, with a prevalence of the recombinant types. These
results coincided with several previous studies based on
the genetic diversity of several major antigens including
circumsporozoite protein, MSP-1, and MSP-3α, as well as
microsatellite loci, suggesting that the Korean P. vivax iso-
lates had been genetically homologous until 2000, but the
genetic diversity was rapidly disseminated thereafter
[26,43]. It is currently unclear why Korean P. vivax isolates
showed such diverse genetic profiles and this issue should
be elucidated. PvMSP-119 was found to be more highly
conserved than PvMSP-133 in the Korean isolates, but the
nucleotide diversity (π) of PvMSP-119 was considerably
higher than those found in previous studies [28,42,44].
This was due to a non-synonymous substitution (N1692K)
in PvMSP-119 of the Korean isolates. Meanwhile, the π
values for PvMSP-142 and PvMSP-133 found in the Korean
isolates were lower than those observed in other global iso-
lates [28,42,44]. This suggests that PvMSP-142 of Korean
isolates showed limited genetic diversity as compared to
isolates from other endemic regions including India and
Sri Lanka.
The rate of non-synonymous and synonymous muta-
tions (dN-dS) is widely used as an indicator of the action
of natural selection in gene sequences. An excess of dN
relative to dS is a clear signal of positive selection,
whereas a lack of dN relative to dS suggests a negative
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[31,45]. The positive value of dN-dS (0.0067) observed in
the 149 Korean PvMSP-142 sequences suggested that
PvMSP-142 in the Korean P. vivax isolates is under the
influence of positive natural selection. The observation
that PvMSP-133 had a higher dN-dS than PvMSP-142
also suggested that PvMSP-133 is under stronger positive
natural selection pressure than the entire PvMSP-142,
and this finding was comparable to observations found
in P. vivax isolates from different areas [28,42]. The posi-
tive values of Tajima’s D (3.0268, P< 0.01) and Fu and
Li’s D (2.0839, P< 0.02) and F (2.9904< 0.02) statistics
indicated that the PvMSP-142 alleles occurred at more
intermediate frequencies than expected and that few
alleles were rare or near fixation, which is consistent
with the action of the balancing selection that maintains
allelic variation in a population. These results collectively
suggested that strong balancing selection, presumably by
host immune pressure [28,45,46], occurred at PvMSP-142
in the Korean isolates, and the host immune responses
likely played a role in generation and maintenance of the
MSP-142 polymorphism.
The diversity of plasmodial antigens is also likely to be
generated by genetic recombination during the sexual
stage of the parasites in the mosquito [45,46]. The results
obtained in this study indicated that recombination
events occurred within the PvMSP-142 sequences in Ko-
rean isolates. This was supported by the observation of
decline of LD index R2 with increasing nucleotide dis-
tance coupled with a high level of haplotype diversity
(Hd = 0.876 ± 0.009). Indeed, all recombinant types of the
Korean PvMSP-142 haplotypes had putative recombin-
ation sites that concentrated in PvMSP-133 rather than
being evenly distributed across the entire PvMSP-142,
which consistent with previous reports [28,41,42]. Con-
sidering the first appearance of the recombinant haplo-
type PvMSP-142 in 2001 and the subsequent prevalence
of recombinant types from 2003 to recent years, new
PvMSP-142 haplotypes are actively being generated in
Korean isolates by recombination events in recent years
even though the country with low malaria transmission
rate.
Conclusion
This study provided the first in-depth analysis of the
genetic diversity and natural selection of PvMSP-142 in
Korean P. vivax isolates. PvMSP-142 showed polymorphic
characteristics that resulted in 11 distinct haplotypes of
the Belem or recombinant types. Most of the observed
amino acid changes were identified in PvMSP-133, but a
novel amino acid change that had not been reported in
global isolates was identified in PvMSP-119. Considering
the low transmission rate and unstable malaria conditions
in Korea, both interallelic and intragenic recombinationsare likely to play roles in the generation and maintenance
of the diversity of PvMSP-142. Furthermore, balancing se-
lection in response to host immune responses may also
contribute to the diversity of PvMSP-142 in Korean iso-
lates. Theses results will be helpful in understanding the
nationwide parasite heterogeneity and the implementa-
tion of malarial control programmes in Korea, as well as
for the development of a PvMSP-1 based vaccine against
P. vivax.
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